In Opdivo + Yervoy vs. Opdivo alone in resected high-risk melanoma and PD-L1

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

The Centers for Medicare & Medicaid Services issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule, which aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior authorization, or ePA, requirements for covered prescription drugs and expedite federal response deadlines to ensure patients receive life-critical medications without administrative delay.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

A meeting convened by Friends of Cancer Research focused on the methodology for using external control arms in cancer clinical trials.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

ACIP charter is renewed as meetings remain on indefinite hold

The Advisory Committee on Immunization Practices, or ACIP, renewed its charter April 6. In an announcement in the Federal Register, new criteria for ACIP members were rolled out with a focus on “geographical balance” and a “balance of speciality areas.”

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

April 17, 2026

By Jacquelyn Cobb

Cancer Policy

Health groups urge Bhattacharya, in his position of acting CDC director, to restore staff in the Office on Smoking and Health

A coalition of public health groups sent a formal letter to NIH Director and Acting CDC Director Jay Bhattacharya April 15 highlighting the need for the immediate restoration of full staffing and resources to the CDC’s Office on Smoking and Health.

April 17, 2026

By Jacquelyn Cobb

In Opdivo + Yervoy vs. Opdivo alone in resected high-risk melanoma and PD-L1 <1% does not meet primary endpoints

YOU MAY BE INTERESTED IN

FDA adds stereotactic breast biopsy needles to the shortage list

CMS proposed rule would implement electronic prior authorization requirements for covered drugs in federal health plans

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

ACIP charter is renewed as meetings remain on indefinite hold

FDA issues reminder to sponsors: Disclose clinical trial results

Health groups urge Bhattacharya, in his position of acting CDC director, to restore staff in the Office on Smoking and Health

Renew today!

Subscriber content

Never miss an issue!

Login